Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Roivant Sciences

< Previous 1 2 Next >
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
From Roivant Sciences
Via GlobeNewswire
Tickers IMVT ROIV ROIVW
Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease
From Roivant Sciences
Via GlobeNewswire
Tickers RHHBY ROIV ROIVW
Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
From Roivant Sciences
Via GlobeNewswire
Tickers IMVT ROIV ROIVW
Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant
From Roivant Sciences
Via GlobeNewswire
Tickers RHHBY ROIV ROIVW
Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Roivant Announces Completion of Redemption of its Outstanding Warrants
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding Warrants
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Roivant to Report Financial Results for the Quarter Ended June 30, 2023, and Provide Business Update on Monday, August 14, 2023
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Roivant Announces Redemption of Outstanding Warrants
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohn’s Disease
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Roivant Ranks No. 25 on Fast Company’s Fifth Annual List of the 100 Best Workplaces for Innovators and is the Winner on the Science and Technology List as a Part of the Best Workplaces for Innovators Program
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
UPDATE -- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provide Business Update on Wednesday, June 28, 2023
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Roivant to Host Investor Call at 8:00 AM ET on Thursday, June 22 to Review Results from the Chronic Period of TUSCANY-2, a Large Global Phase 2b Study of RVT-3101 (Anti-TL1A Antibody) in Ulcerative Colitis
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Roivant to Host Investor Call at 8:00 AM ET on Wednesday, March 15 to Review Results from ADORING 2 Phase 3 Trial in Atopic Dermatitis
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Proteovant Therapeutics to Present Preclinical Data from Estrogen Receptor and IKZF2 Protein Degrader Programs
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Covant Therapeutics Announces the Formation of its Scientific Advisory Board to Support Platform and Pipeline Advancement
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Roivant Sciences Announces Change to its Board of Directors
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Roivant Sciences Reports Financial Results for the Third Quarter Ended December 31, 2022 and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Roivant Sciences Announces Pricing of Upsized Public Offering of Common Shares
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Roivant Sciences Announces Proposed Public Offering of Common Shares
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.